Background: Dexmedetomidine (Dex) is a sedative agent with analgesic property.
Analgesic sparing effects of Dexmedetomidine in surgical intensive care patients Sheikh et al.
were recorded. Patients were intubated and ventilated, the initial dose of Dex infusion was 0.5 mcg/kg/hr along with either fentanyl or remifentanil infusion. Dex infusion was titrated to keep the Ramsay sedation score of 3 to 4. Analgesia was titrated according to the NRS (numeric rating scale) in extubated patients and the Critical-Care Pain Observation Tool (CPOT) score in intubated patients. The infusion of fentanyl and remifentanil were titrated and decreased according to the CPOT score. Some of the patients extubated required continuation of the Dex infusion in the post-extubation period to maintain analgesia and to keep them calm.
Chi-square test was performed to compare among the groups. P-value # 0.05 was considered as statistically significant. Results: A total of 428 patients were enrolled in the study. The majority of patients were male (73.3%). The most common diagnosis was acute abdomen and frequently the performed surgery was laparotomy (28.9%) (Figure 1a ). The duration of Dex treatment ranged from 2 to 28 days; the most commonly used dose was 0.5 to 1.4 mg/kg/ hours (Figure 1b) . Seventy-eight percent (78%) of patients required Dex in the postextubation period at a dose of 0.2 mg /kg/ hours. There was significant reduction in the analgesic requirements in the post-Dex 
